Clinical guideline highlights for the hospitalist: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy

Saurabh D Chitnis; Amir Mortazavi

doi:10.1002/jhm.13097

Clinical guideline highlights for the hospitalist: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy

J Hosp Med. 2023 Nov;18(11):1013-1016. doi: 10.1002/jhm.13097. Epub 2023 Apr 11.

Authors

Saurabh D Chitnis¹, Amir Mortazavi¹

Affiliation

¹ Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.

PMID: 37039096
DOI: 10.1002/jhm.13097

Abstract

Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update RELEASE DATE: November 1, 2021 PRIOR VERSION(S): February 14, 2018 DEVELOPER: American Society of Clinical Oncology FUNDING SOURCE: American Society of Clinical Oncology TARGET POPULATION: Adult patients with cancer receiving treatment with immune checkpoint blockade inhibitors alone.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Hospitalists*
Humans
Immune Checkpoint Inhibitors*

Substances

Immune Checkpoint Inhibitors